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A B S T R A C TObjectives: In the Italian health care system, genetic tests for factor V
Leiden and factor II are routinely prescribed to assess the predisposi-
tion to venous thromboembolism (VTE) of women who request oral
contraception. With speciﬁc reference to two subpopulations of women
already at risk (i.e., familial history or previous event of VTE), the study
aimed to assess whether current screening practices in Italy are cost-
effective. Methods: Two decisional models accrued costs and quality-
adjusted life-years (QALY) annually from the perspective of the
National Health Service. The two models were derived from a decision
analysis exercise concerning testing practices and consequent prescrib-
ing behavior for oral contraception conducted with 250 Italian gynecol-
ogists. Health care costs were compiled on the basis of 10-year hospital
discharge records and the activities of a thrombosis center. Whenever
possible, input data were based on the Italian context; otherwise, the
data were taken from the international literature. Results: Currentsee front matter Copyright & 2013, International S
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ilan, Italy.testing practices on women with a familial history of VTE generate an
incremental cost-effectiveness ratio of €72,412/QALY, which is well
above the acceptable threshold of cost-effectiveness of €40,000 to
€50,000/QALY. In the case of women with a previous event of VTE,
the most frequently used testing strategy is cost-ineffective and leads
to an overall loss of QALY. Conclusions: This study represents the ﬁrst
attempt to conduct a cost-utility analysis of genetic screening practices
for the predisposition to VTE in the Italian setting. The results indicate
that there is an urgent need to better monitor the indications for which
tests for factor V Leiden and factor II are prescribed.
Keywords: cost-utility analysis, genetic testing, Italy, venous throm-
boembolism.
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Genetic testing is progressively entering clinical practice and
screening programs. It is estimated that genetic tests are available
for more than 1300 diseases, including those detecting predisposi-
tions to common multifactorial diseases or such conditions as
cancer, diabetes, hypertension, psychological disorders, and defec-
tive drug metabolism [1]. Health policymakers in several industri-
alized countries have recognized that the rapid technological
progress in this ﬁeld and the rising interest of people in genetic
information necessitate more strategic planning and a better
assessment of the real beneﬁts brought by genomic medicine [2].
There is a general consensus that most genetic tests intro-
duced in health care systems since the late 1990s were “riding a
wave of enthusiasm rather than evidence” [3]. These tests’
uncontrolled spread might be due to a combination of reasons.
Producers of in vitro diagnostics are subject to a loose regulatoryregime, both in the United States and in Europe, which allows
tests to be marketed without having to prove their clinical validity
or utility in randomized controlled trials [4,5]. Furthermore, so-
called home brews are rather common. These tests are optimized
by hospitals and laboratories for research purposes; however,
because of the lack of quality control programs for most genetic
tests, the tests end up being used for medical applications with
poor monitoring of their actual utilization [6]. Finally, genetic tests
can be directly advertised to consumers through the Internet, and,
as such, they are more prone to be introduced on the basis of a
commercial rather than scientiﬁc or medical basis [7]. Given these
dynamics, genetic tests might be able to diffuse easily into health
care systems with little chance for policymakers to actually
predict their impact and control that tests are actually used on
those who can beneﬁt the most from their predictive power.
In this scenario, evaluation frameworks for the assessment of
genetic tests are still scarce. The so-called ACCE [8] andociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 9 0 9 – 9 2 1910Evaluation of Genomic Applications in Practice and Prevention [9]
are the most well-established, though still rarely used, frame-
works. These frameworks propose that both the analytical and
clinical validity and the clinical utility of genetic tests should be
clearly established before introducing a new test or deciding its
reimbursement by third-party payers. Moreover, the ACCE frame-
work indicates the need to include economic evaluations to
support this type of decision. Despite the economic evidence
accumulating in the literature regarding genetic testing [10–12], it
is argued that economic analyses, besides presenting several
methodological challenges [13], have had little impact to date in
informing policies and reimbursement practices concerning
genetic testing [3]. The analyses are of highly variable quality,
and, particularly for cost-utility studies that would allow an easy
comparison of genetic testing with other health care interven-
tions, are rather uncommon [10].
Given the challenges in assessing diagnostics and devices
through experimental studies, such as randomized controlled
trials [13], in this study, we start from the perspective that
economic analyses and health technology assessments should
aim at informing current clinical practice and optimizing the
utilization of genetic tests, rather than attempting to curb their
initial introduction. The viewpoint is consistent with the broader
recommendations of the HTAi Policy Forum in 2009 [14] and with
more recent work by the ISPOR Good Research Practices Task
Force on Observational Studies that has highlighted the relevance
—and good practice—of using real-world data to inform decision
makers [15–18]. As such, to provide valid information to prescrib-
ing clinicians and policymakers, economic evaluations should be
based on the best available knowledge of how and why genetic
tests are prescribed and used in current practice.
To address this issue, the present work explores the speciﬁc
instance of genetic tests for the predisposition to venous throm-
boembolism (VTE). VTE is a multifactorial disease caused by a strong
interplay between environmental and genetic factors [19], with an
incidence ranging from 7 to 18 per 10,000 person-years according to
the geographic area [20–24]. VTE consists of a milder form, deep-vein
thrombosis (DVT), and a more severe condition, pulmonary embo-
lism (PE), which has been shown to account for 10% of hospital
deaths [25–27]. Three genetic defects have been proven to predis-
pose patients to VTE: factor V Leiden (FVL; Arg506Gln substitution),
factor II/prothrombin (FII; G20210A polymorphism), and methylene-
tetrahydrofolate reductase (C677T polymorphism) [28]. The like-
lihood of developing VTE is further augmented in such situations
as pregnancy, oral contraception use, forced immobilization (e.g.,
long-distance ﬂight), and major surgery.
Since the late 1990s, the tests detecting the above-mentioned
three most important genetic alterations have been among the ﬁrst
to enter clinical practice. Italy is no exception to this trend, and,
overall, more than 60,000 tests —approximately a quarter of all
molecular ones—are conducted every year in the country to screen
for predisposition to VTE [29,30]. The expenditure for these tests
can be estimated to be approximately €18 million per annum; still,
a rather limited amount of money. The main concern, though,
derives from the sharp increase in the number of tests over recent
years (e.g., there was a 50% increase between 2004 and 2007) [30].
This information is particularly relevant, given that all tests for
thrombophilia are reimbursed by the Italian National Health
Service (NHS) and that to date, national and international medical
associations have produced notably cautious recommendations
concerning the use of these tests [e.g., 31–33].
Economic analyses in this ﬁeld are rather rare but have
provided evidence that universal screening for the predisposition
to VTE is not a worthwhile investment of public resources [34–36].
For instance, Wu et al. [36] showed that screening for this
predisposition in all women administered oral contraceptives
would impose an additional cost of £200,000 to avoid one VTEevent. Even considering more targeted populations, such as those
at high risk of VTE because of a family or personal history of the
condition, the results are not always consistent nor do they show
clear cost-effectiveness, if compared with the cost-effectiveness
threshold of €40,000/quality-adjusted life-year (QALY).
In the present study, we considered the application of genetic
testing for the predisposition to VTE of broad relevance for public
health, namely, that for women already at risk who are seeking
oral contraception. We adopted the perspective of the third-party
payer (i.e., the Italian NHS) and attempted to answer the follow-
ing questions: what are the costs and the beneﬁts of the current
screening practice in the Italian setting? On what aspects could
policymakers and clinicians leverage to improve the effectiveness
of the current testing practice and reduce the associated costs?Methods
A cost-utility model was developed to compare costs and utilities
associated with different practices of genetic screening for 15- to 45-
year-old women at high risk of VTE who visit a gynecologist for a
prescription for the oral contraceptive pill (OCP). To identify current
genetic screening practices in Italy, a questionnaire was designed in
collaboration with a group of three gynecologists. The questionnaire
presented two different scenarios (scenario 1: familial history;
scenario 2: previous event of VTE) and recorded the decisions
normally made by gynecologists when facing these clinical cases.
Unlike the study by Wu et al. [36], the two scenarios were kept
separate because they might be associated with a different percep-
tion of risk by clinicians. In both scenarios, the questionnaire referred
to “idiopathic VTE,”which is an event that had arisen spontaneously
and was not induced, for instance, by a surgical operation.
The questionnaire was ﬁrst validated by eight gynecologists,
modiﬁed, and converted into an electronic platform. The question-
naire was subsequently disseminated by e-mail through the Italian
Society of Gynecologists and Obstetricians (Società Italiana di
Ginecologia e Ostetricia [SIGO]). Invitations to respond to the
survey were sent to 1000 randomly selected SIGO members and
contained a unique personal link to the questionnaire. In total, 250
gynecologists completed the questionnaire for a response rate of
25%. The respondents were homogeneously distributed across the
country (northern Italy: 32%; central Italy: 30%; southern Italy: 38%).
In the attempt to reproduce as closely as possible the Italian
clinical practice, the model structure and parameters were
derived from survey results. First, two different courses of action
were reported, depending on the scenario (i.e., whether the
woman had a familial history of VTE or had experienced a VTE
event herself). More speciﬁcally, in the case of familial history of
VTE (scenario 1), the great majority of gynecologists prescribed a
battery of biochemical and genetic tests (69.3%), while the rest
were equally split between those who prescribed biochemical
tests only (13.4%) or genetic tests only (13.4%). In contrast, when
facing a case of previous VTE event (scenario 2), gynecologists
mostly tended either to prescribe a battery of biochemical and
genetic tests (65.1%) or not to conduct any screening and avoid
OCP prescription altogether (24.1%). The strategies to be included
and compared in the two models (i.e., for scenario 1 and for
scenario 2) were derived from these results (see the following
section for a more detailed description of the models’ structure).
Second, the probabilities of subsequent therapeutic choices by
gynecologists (i.e., to prescribe or not OCP) in face of positive
biochemical and/or genetic test results were also derived from
the survey results (see details in the Appendix in Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2013.05.003).
The ﬁndings showed that gynecologists consistently perceived
the case of a previous VTE event to be riskier compared with a
familial history of VTE, even if the scientiﬁc evidence suggests
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Fig. 1 – Schematic representation of the decision trees for the two clinical scenarios. The black square represents the decision
node with options speciﬁed below for the two scenarios, while circles indicate the chance events with probabilities that were
identiﬁed on the basis of survey results of Italian gynecologists. (A) Scenario 1 (familial history of VTE). The three alternative
strategies considered are the following: i) screen only with a battery of biochemical tests (Screen BIO, baseline strategy), ii)
screen only with a battery of genetic tests (Screen GEN, Strategy 1), and iii) screen with a battery of both biochemical and
genetic tests (Screen BIO/GEN, Strategy 2). (B) Scenario 2 (previous VTE event). The two alternative strategies considered are the
following: i) screen with a battery of both biochemical and genetic tests (Screen BIO/GEN, Strategy 3) and ii) no screening and
no oral contraceptive pill (baseline strategy). Btest (Gtest) þve (−ve), women screened with biochemical (genetic) tests who
result in a positive (negative); false Btest (Gtest) þve (−ve), women screened with biochemical (genetic) tests who result in a
false positive (negative); OCP, oral contraceptive pill; VTE, venous thromboembolism.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 9 0 9 – 9 2 1 911the opposite [37,38]. The probability of denying OCP when the test
results were positive was always higher in the former case (96%
vs. 86% in case of positive biochemical test results, 98% vs. 85% in
case of positive genetic test results, and, ﬁnally, 100% vs. 98% incase of positive genetic and biochemical test results). This
attitude was further conﬁrmed by the fact that with a previous
VTE event, more than 60% of the gynecologists did not prescribe
OCP, even when all test results were negative.
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Decision tree techniques were used to evaluate the two separate
scenarios that were identiﬁed from the survey results and that
thus can be considered practical and feasible within the Italian
health system: familial history of VTE (scenario 1) and previous
VTE event (scenario 2). In particular, for scenario 1, the following
two strategies were evaluated: Strategy 1: genetic tests only. In the model, this strategy was
compared with biochemical tests only, which was the baseline
option for scenario 1 Strategy 2: biochemical and genetic tests combined. In the model,
this strategy was compared with biochemical tests only (baseline
option). Indeed, the focus of this comparison was to evaluate
the additional beneﬁts and costs of genetic tests as opposed to
usual practice. Genetic tests have been introduced into clinical
practice later than biochemical tests and can therefore be
used in alternative or in combination with biochemical tests.
For scenario 2, the following strategy was evaluated: Strategy 3: biochemical and genetic tests combined. In the model,
this strategy was compared with no test and no oral contraceptive
prescription, which was the baseline option for scenario 2.
In Figure 1, the two trees developed for scenarios 1 and 2,
respectively, are schematically represented. The structure of both
trees was designed to follow over their lifetime a cohort of
women aged 15 to 45 years who visit gynecologists for OCP
prescriptions. Each tree is organized according to the following
steps:1) a decision node that represents the strategy evaluated;
2) chance nodes for the probabilities of having biochemical and/
or genetic mutations;
3) chance nodes representing the conditional probabilities of the
gynecologist prescribing the contraceptive pill once tests
results are known; and ﬁnally,4) chance nodes for outcomes events (VTE and/or related
sequelae).
Consistent with other studies [34,36,39,40], we incorporated in
our model a number of sequelae that may result from an episode
of VTE. In particular, in the case of PE, these sequelae included a
recurrent VTE event, hemorrhage due to warfarin, and pulmo-
nary hypertension (PH). In women experiencing DVT, postthrom-
botic syndrome (PTS) was introduced in the model instead of PH.
Unlike other studies, we also included among the sequelae acute
myocardial infarction (AMI) and stroke. This inclusion was
deemed necessary based on recent scientiﬁc evidence that shows
the correlation between VTE and acute arterial cardiovascular
events [41]. In addition, we took into account the increased risk of
VTE due to an unwanted pregnancy [42] and included this
possibility in all branches of the decision tree in which a woman
was denied oral contraception and had to use an alternative
method [43]. Condoms (90% of cases) and diaphragms (10%)
emerged from the survey with gynecologists as the two most
frequently suggested alternative contraceptive methods.
Model Parameters
Epidemiology and utility values
Table 1 summarizes the baseline parameter values with ranges
and related data sources. The overall probability of developing
VTE (both PE and DVT) depended on the following: a) the
presence of the individual mutations detected through genetic
and/or biochemical tests, which depends on the prevalence of
these mutations in the population [31,57,58], as well as the
positive predictive value of the test whereby the sensitivity andspeciﬁcity of genetic and biochemical tests were derived fromWu
et al. [36]; b) the incidence of VTE in the population; and c) the
probability of being prescribed OCP, which was derived from
survey results.
The baseline incidence of VTE, the proportions of idiopathic
VTE, PE, and DVT, and the probabilities of developing sequelae
were derived from an extensive review of the published liter-
ature, and whenever possible, input data were extracted from
longitudinal studies [19,21,41,45,48–50]. Alternatively, large stud-
ies focusing on young women (i.e., our study population) were
used for deriving estimates of model parameters. Being aware
that the estimates of VTE incidence are uncertain, we started
from a rather conservative estimate of 4.03 new events per 10,000
person-year, as indicated by Lidegaard et al. [44] for women aged
between 15 and 49 years. The baseline incidence of VTE was
modiﬁed in the two scenarios on the basis of the fact that a
woman with a familial history of VTE has three times the
probability to incur VTE than the overall population [37], while
for a person with a personal history of VTE, the relative risk of
recurrence is 1.71 [38]. To obtain the ﬁnal incidence of VTE in the
two subpopulations at risk, we considered that only 36.5% of all
cases of VTE are idiopathic [19]. We subsequently conducted a
sensitivity analysis on this parameter.
The odds ratios for a woman to incur a VTE when positive for
genetic alterations (those detected by either genetic or biochem-
ical tests) or when prescribed OCP were derived from three main
meta-analyses [28,46,47]. The average of the odds ratios relative
to FVL and FII and to Protein S (PS), Protein C (PC), and
Antithrombin III (ATIII) was later used in the models.
Case-fatality ratios, instead, were taken only marginally from
the literature [49] and were derived, for the rest, from national
databases on death causes in 2002 compiled by the Italian
National Statistics Ofﬁce [59] and, for DVT and PE, from a regional
discharge record database referring to years 1997 to 2007 (for
more details on this latter database, see the following section on
cost). All discharge records were linked with the data from the
General Register Ofﬁce of births and deaths, allowing capturing
VTE-related fatality during both hospital stay and postdischarge.
Finally, utility values were taken from an extensive literature
review that, wherever possible, aimed at identifying estimates
derived from female population in the age range of interest
[51–55]. Utility weights as reported in previous works and in
Table 1 with related conﬁdence intervals were used to calculate
the average discounted QALY lost per VTE-related event given
the probability to survive to a certain age (derived from the
background mortality rates for the general Italian population)
and the age-speciﬁc background quality-of-life weights, as
derived by Kind et al. [60]. In the cases of PH and PTS, we
retrieved notably few references [52,55], and thus an extensive
sensitivity analysis was performed.
Cost Data
Consistent with the study perspective, only direct costs borne by
the health care system were considered. To measure the costs of
treating VTE to the Italian NHS, we devised a new approach that
exploited the richness of the available Italian administrative
hospital data set to conduct microcosting. We obtained the
complete hospital discharge records of all cases of DVT and PE
(primary diagnosis as reported in the ﬁrst diagnostic ﬁeld) from
one Italian region (Friuli Venezia Giulia; population in 2007:
1,188,291 inhabitants) for the period between 1997 and 2007.
Discharge records in Italy contain a considerable amount of
clinical data, including diagnosis, admission and discharge
departments and dates, and up to six procedures (surgical,
diagnostic, or other clinical intervention) that the patient has
undergone while in the hospital. Nevertheless, these are mainly
Table 1 – Model parameters and ranges used in the probabilistic sensitivity analysis.
Model parameters Base-case
value
Range* Reference or data source
Epidemiology
VTE incidence rate, females 15–49 y (per 10,000) 4.030 3.91–4.16 [44]
Fold increase in VTE risk with familial history 3.000 2.3–4 [37]
Fold increase in VTE risk with personal history 1.710 1.16–2.252 [38]
Proportion of idiopathic VTE 0.365 0.27–0.46 [19]
Proportion of PE 0.205 – [21]
Proportion of DVT 0.795 – [21]
Case-fatality ratio for DVT 0.007 0.33%–1.28% Hospital discharge records
(FVG, 1997–2007)
Case-fatality ratio for PE 0.045 3.1%–6.53% Hospital discharge records
(FVG, 1997–2007)
Case-fatality ratio for AMI 0.144 14%–14.7% National hospitalization data
and death statistics (2002)
Case-fatality ratio for ischemic stroke 0.059 5.53%–6.24% National hospitalization data
and death statistics (2002)
Case-fatality ratio for hemorrhagic stroke due to warfarin 0.113 7.5%–15.9% [45]
Case-fatality ratio for recurrent VTE event 0.113 8%–15.2% [45]
OR for antithrombin deﬁciency and VTE risk 3.180 0.82–12.29 [46]
OR for protein C deﬁciency and VTE risk 2.450 1.18–5.11 [46]
OR for protein S deﬁciency and VTE risk 5.310 2.48–11.37 [46]
OR for factor V Leiden (heterozygous) mutation and VTE risk 4.930 4.41–5.52 [28]
OR for prothrombin (factor II) mutation and VTE risk 3.170 2.19–3.46 [28]
OR for OCP use and idiopathic VTE 4.470 2.84–7.03 [47]
OR for FV mutation, OCP use, and VTE risk 1.800 1.2–2.71 [47]
OR for prothrombin mutation, OCP use, and VTE risk 1.630 1.01–2.65 [47]
OR for antithrombin mutation, OCP use, and VTE risk 12.600 1.37–115.79 [46]
OR for protein C deﬁciency, OCP use, and VTE risk 6.330 1.68–23.87 [46]
OR for protein S deﬁciency, OCP use, and VTE risk 4.880 1.39–17.1 [46]
Unwanted pregnancy among diaphragm users 0.060 0.05–0.16 [43]
Unwanted pregnancy among condom users† 0.050 0.04–0.21 [43]
Fold increase in VTE risk due to pregnancy 4.200 0.9–19.9 [42]
Sequelae
Probability of AMI after idiopathic DVT 0.763% 0.005–0.009 [41]
Probability of stroke after idiopathic DVT 6.181% 0.046–0.077 [41]
Probability of PTS after DVT 17.300% 0.129–0.216 [48]
Probability of AMI after idiopathic PE 0.979% 0.007–0.012 [41]
Probability of stroke after idiopathic PE 4.421% 0.033–0.055 [41]
Probability of chronic PH after idiopathic PE 3.100% 0.007–0.055 [49]
Probability of recurrent VTE in women 10.900% 0.081–0.136 [50]
Probability of hemorrhagic stroke post-VTE 2.100% 0.016–0.026 [45]
Baseline utilities
DVT 0.931 0.79–1 [51]
PE 0.855 0.73–0.98 [51]
PTS 0.982 0.96–1 [52]
Stroke‡ 0.523 0.446–0.598 [53]
AMI 0.945 0.933–0.958 [54]
PH 0.900 0.875–0.925 [55]
Economic variables (in €)
Costs of testing
Cost of battery of biochemical tests 21.7 16.2–27.1 Galliera Hospital (budgeting
and accounting ofﬁce [BAO])
Cost of battery of genetic tests 100.5 75.3–125.6 Galliera Hospital (BAO)
Hospitalization costs
Cost per day in the hospital for DVT 198 148.5–247.6 Galliera Hospital (BAO)
Cost per day in the hospital for PE 325 244–406.7 Galliera Hospital (BAO)
Length of stay in the hospital for DVT (d) 11 0–∞ Hospital discharge records
(FVG, 1997–2007
Length of stay in the hospital for PE (d) 13 0–∞ Hospital discharge records
(FVG, 1997–2007)
Average cost of hospital diagnostic and surgical procedures for DVT 145.1 66.5–110.8 Galliera Hospital (BAO)
Average cost of hospital diagnostic and surgical procedures for PE 220.4 173.5–289.2 Galliera Hospital (BAO)
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Table 1 – continued
Model parameters Base-case
value
Range* Reference or data source
Average cost of pharmacological treatment in hospital for DVT 141.0 105.7–176.2 Galliera Hospital (BAO)
Average cost of pharmacological treatment in hospital for PE 141.0 105.7–176.2 Galliera Hospital (BAO)
Posthospitalization diagnostic and pharmacological treatment
Average cost of treatment at thrombosis center after DVT (length of
treatment 3 mo)
146.74 110–183.4 Drug prices— National
formulary
Average cost of treatment at thrombosis center after PE (length of
treatment 6 mo)
273.71 205.2–342.1 Drug prices— National
formulary
Overall average cost per DVT case 2602.78 – Derived from above values
Overall average cost per PE case 4847.80 – Derived from above values
Costs of sequelae
Average cost of AMI 9992.92 7494.6–12491.1 Galliera Hospital (BAO)
Average cost of ischemic stroke 4768.69 3576.5–5960.8 Galliera Hospital (BAO)
Average cost of PTS 2317.77 1738.3–2897.2 Galliera Hospital
(BAO; years 2006–2009)
Average cost of PH 2868.15 2151.1–3585.1 Galliera Hospital
(BAO; years 2006–2009)
Average cost of hemorrhagic stroke 14776.49 11082.3–
18470.6
Galliera Hospital (BAO)
Average cost of unwanted pregnancy 3752 2814–4690 [56]
AMI, acute myocardial infarction; DVT, deep-vein thrombosis; FVG, Friuli Venezia Giulia; OCP, oral contraceptive pill; OR, odds ratio; PE,
pulmonary embolism; PH, pulmonary hypertension; PTS, postthrombotic syndrome; VTE, venous thromboembolism.
 When reported values were derived from the literature, the range refers to a 95% conﬁdence interval.
† Assuming perfect use of the contraceptive method.
‡ Weighted average of age-stratiﬁed values reported in Cadilhac et al. [53].
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miological analyses. A total of 6988 discharge records were
extracted and analyzed. Of these, 3721 were cases of DVT
(International Classiﬁcation of Diseases, Ninth Revision, Clinical Mod-
iﬁcation [ICD-9-CM] codes 451.11, 451.19, 453.2, 453.3, 453.8, and
453.9) and 3267 of PE (ICD-9 CM code 415.19). Nonidiopathic VTE
cases were not included in the data set and in the following
analysis. In addition, patients with cancer were excluded from
the sample because this condition might induce VTE [61] and
thus the patients would not match our case deﬁnition of
idiopathic VTE.
From each record we derived the following information: 1) the
main procedures (i.e., diagnostic and surgical) performed on
patients with DVT and PE; 2) the length of stay in the hospital;
and 3) the hospital department in which patients were admitted
and treated.
Monetary values were attributed to health care resources on
the basis of data provided by the Galliera Hospital, Genoa, and
referring to the year 2009 (Table 1). The hospital presented a
reliable and detailed accounting system and was able to provide
costs of hospital departments subdivided in personnel, proce-
dures, pharmaceuticals, and overheads. In this way, it was
possible to calculate the average cost of 1 day in a speciﬁc
hospital department based only on personnel and overheads.
We then added to this the cost items speciﬁc to the cases of DVT
and PE and, in particular, procedures and pharmacological treat-
ments. The hospital, in fact, had conducted a thorough activity-
based costing exercise for most of its procedures, including those
of interest for DVT and PE. We identiﬁed from the discharge
records roughly 20 procedures (see Appendix 1 in Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2013.05.003 for
details) that constituted more that 90% of all procedures per-
formed for DVT and PE and obtained from the hospital the related
costs. In this way, it was possible to populate the two models
with actual cost values, rather than tariffs. Similarly, the hospitalhad calculated through activity-based costing the costs for its
own laboratory of conducting genetic tests for FVL, FII, and
methylenetetrahydrofolate reductase (€100.5) and to perform
biochemical test for proteins C and S and antithrombin III
(€21.7; Table 1).
For the pharmacological treatment of DVT and PE in the
hospital and after discharge, we consulted the director of the
thrombosis center of the Galliera Hospital, who provided us with
the patterns of pharmacological therapy for these cases, names
of drugs, doses, and average lengths of treatment after discharge
(3 months for DVT and 6 months for PE). After discharge, the
anticoagulant therapy with warfarin is normally accompanied by
some monitoring examinations (e.g., international normalized
ratio and D-dimer tests) that were also valued into the ﬁnal
calculation. To attribute monetary values to the pharmaceuticals,
we used national prices, as indicated in the national drug
formulary [62]. In the Italian context, the great majority of
women visit gynecologists working in private practice for OCP
prescription and pay for their own contraceptive pills. As such,
these costs were not included in the calculations.
For consistency, the total direct costs for all cases of AMI (ICD-9-
CM code 410) and hemorrhagic (ICD-9-CM codes 430, 431, and 432)
and ischemic (ICD-9-CM codes 433, 434, and 436) stroke in 2009 and
for all cases of PH (ICD-9-CM codes 416.8 and 416.9) and PTS (ICD-9-
CM code 459.1) between 2006 and 2009 were provided by the
Galliera Hospital and used in the models for costing VTE sequelae.
As such, these costs referred only to the acute phase of the
sequelae, that is, in-patient treatment, and are likely to under-
estimate the overall costs of these pathologies. The costs associated
with an unwanted pregnancy were derived from the literature [56].
Analyses
Decision trees were developed by using the software Precision
Tree 1.0 (Palisade Corporation, Newﬁeld, NY). In particular, two
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 9 0 9 – 9 2 1 915separate trees (for each scenario under consideration) were
developed. Costs and QALY lost were generated for each scenario
and compared with the baseline alternative by using discount
rates at 3.5% per annum as recommended by the National
Institute for Clinical Excellence [63]. Based on the modeling
predictions, the incremental cost-effectiveness ratios (ICERs) of
the considered screening strategies compared with the baseline
strategy were calculated.
To evaluate the effects on the estimated ICERs of changes in
several model parameters that are believed to be highly uncer-
tain, one- and two-way sensitivity analyses were performed. In
these analyses, one- (or two)-model parameters were varied
arbitrarily while holding all the others parameters constant at
their base-case values, and the ICERs were derived. The effects of
changing the following model parameters were evaluated: a) VTE
incidence rates in the selected population, b) cost of the genetic
tests, c) QALY lost for the main outcomes (PE and DVT), and d)
fold increase in VTE risk during pregnancy.
Probabilistic sensitivity analysis using Monte Carlo simula-
tions was also performed (3000 iterations) to determine how the
underlying uncertainty of all model parameters would project on
the uncertainty around the ICER and was subsequently trans-
lated in the ﬁnal interpretations of the models’ results. Beta
distributions were used for utilities and probabilities to restrict
the possible values to be between 0 and 1 [64]. Gamma distribu-
tions were used for all model costs with the exclusion of the costs
for the genetic and biochemical tests, which were assumed to
follow a beta distribution with ﬁxed lower and upper bounds
(25% of the average cost). The gamma distribution restricts
values to be above 0, but it is otherwise similar to a normal
distribution. In particular, for the length of stay in the hospital
and the costs of sequelae, gamma distributions were ﬁtted to
hospitalization data and were used in the Monte Carlo sampling
procedure.Results
Base-Case Analysis
Under scenario 1 (familial history of VTE), the current practice
that sees most gynecologists add genetic tests to the more
traditional biochemical tests to assess the thrombophilic proﬁle
of their patients (strategy 2) does not meet a cost-effectiveness
threshold of €40,000 to €50,000/QALY (Table 2) [65]. The estimatedTable 2 – Scenario 1 (familial history of VTE): incremental c
comparing the strategy of prescribing a battery of bioche
tests only.
20
Incidence rate per 10,000 of idiopathic VTE in
women with a familial history
2 31,023
3 20,223
4.4 13,307
5 11,583
6 9,423
7 7,880
8 6,723
Notes: ICER values are provided for alternative levels of the incidence ra
lower values used for the sensitivity analysis were derived from the
geneticists (costs of genetic tests). In bold, the ICER value corresponds to
which ICER values are within the threshold of cost-effectiveness of €40,
ICER, incremental cost-effectiveness ratio; VTE, venous thromboembolisICER (€72,412/QALY), indeed, compares unfavorably to this
threshold. With an ICER of €171,584/QALY gained, the prescrip-
tion of only genetic tests in alternative to biochemical tests is
even less cost-effective.
Under scenario 2 (previous event of VTE), the strategy of
prescribing a battery of biochemical and genetic tests is domi-
nated by the no-test and no-OCP strategy. The former strategy
favors a riskier behavior and therefore generates QALY loss. The
reason for this result is that the risk of VTE (and consequently
QALY loss) is considerably augmented by the prescription of OCP
and driven mainly by this factor. While in the “battery of
biochemical and genetic tests” strategy, OCP is prescribed accord-
ing to probabilities derived from the survey on gynecologists, in
the no-test and no-OCP strategy, instead, OCP is not prescribed at
all and, as such, less QALYs are lost because of VTE. In Appendix
1 in Supplemental Materials found at http://dx.doi.org/10.1016/j.
jval.2013.05.003 (Table A1.3), detailed values of costs, effects of
each of the above strategies, and incremental costs and effects
derived from comparing strategies are reported.Sensitivity Analysis
The strategy of using a battery of biochemical and genetic tests
for a woman with a familial history of VTE (scenario 1) instead of
only biochemical tests met the cost-effectiveness threshold of
€40,000/QALY for either higher levels of VTE incidence in the
population or for lower costs of the genetic test (Table 2). More
speciﬁcally, keeping the incidence of VTE at baseline value
(approximately 4.4 per 10,000), the ICER would fall below the
threshold if costs of the genetic tests would be as low as in the
range of €40 to €60. Conversely, keeping the cost of genetic tests
constant at baseline value (€100), the ICER would fall below the
threshold value only when the incidence of VTE was doubled
(8 per 10,000), while keeping the other parameters constant. This
result, however, depends on model assumptions and particularly
on the risk of unwanted pregnancy in women to whom OCP is not
prescribed and, more directly, to the assumed fold increase in
VTE incidence in this subpopulation. In Figure 2, the sensitivity of
model results is shown for different values of VTE incidence in
the subpopulation and of the fold increase in the risk of VTE
during pregnancy (in this case, unwanted pregnancy resulting
from OCP denial and the need to use less effective contraceptive
methods). As evident from Figure 2, these two variables have
opposite effects on the resulting ICER values. The higher the
incidence of VTE, the more QALYs are gained by testing both withost-effectiveness ratios (euro/QALY) obtained when
mical and genetic tests vs. prescribing biochemical
Cost of genetic tests (€)
40 60 80 100.5 120 140
63,423 95,824 128,224 161,434 193,024 225,424
41,823 63,423 85,024 107,164 128,224 149,824
27,992 42,676 57,361 72,412 86,730 101,414
24,543 37,503 50,463 63,747 76,383 89,344
20,223 31,023 41,823 52,893 63,423 74,223
17,137 26,395 35,652 45,140 54,166 63,423
14,823 22,923 31,023 39,326 47,223 55,323
te of idiopathic VTE and of the cost of the genetic tests. Upper and
literature (incidence rate of VTE) or from the consultation of four
the base case (€72,412); the values in italic indicate the conditions in
000/QALY.
m; QALY, quality-adjusted life-year.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 9 0 9 – 9 2 1916a combination of genetic and biochemical tests and with only
biochemical tests but to a higher degree in the former option.
Therefore, the value of the ICER decreases or, in other words, the
combined strategy meets the cost-effectiveness threshold of
€40,000/QALY. The higher the risk of VTE during pregnancy,
however, the lower is the QALY gain obtained through both
testing strategies. This effect is more prominent for the combi-
nation testing option, driving up the value of the ICER and
making the strategy even less cost-effective than in the baseline
case. The balance between the two variables might make the
difference between being the combination strategy cost-effective
or not, based on the above cost-effectiveness threshold. For
instance, in a situation in which the incidence of VTE is 8 per
10,000, testing with a battery of genetic and biochemical tests is
cost-effective only if the fold increase in VTE during pregnancy
does not exceed 5.
The model was fairly robust to changes in utility values once
VTE occurs (both PE and DVT) and even to variations in QALYsA
B
0
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Fig. 2 – Opposite effects on the cost-effectiveness results in unce
risk and in the fold increase in VTE incidence during pregnancy (
VTE incidence rates with range: 4 to 18 per 10,000 and baseline:
with range: 2 to 10 per 10,000 and baseline: 2.52. ICER, incremenfollowing the occurrence of sequelae such as stroke, AMI, PTS,
and PH, probably due to the low incidence of these events. In the
baseline analysis, a case of DVT or of a nonfatal PE was estimated
to cause, on average, a loss of 1.61 and 3.39 QALY, respectively,
for an otherwise healthy 15- to 45-year-old woman. Increases in
DVT and PE utility weights, however, had to be rather relevant
(discounted QALY lost for a DVT event greater than 5) to out-
weigh the costs associated with the prescription of genetic tests
and to reduce the cost-effectiveness ratio to an acceptable level, if
compared with the cost-effectiveness threshold of €40,000/QALY
(data not shown).
In the case of scenario 2 (previous event of VTE), diminishing
the cost of the genetic tests does not have a signiﬁcant effect on
the ICER (data not shown). In addition, in scenario 2, the
incidence of VTE and the risk of VTE during pregnancy have
opposite effects on the ICER values, which remain, in any case,
negative for all realistic ranges of parameters, due to QALY loss
(Fig. 2). In this scenario, though, the interpretation of results is12 14 16 18
e rate per 10,000
2
4.2
6
8
6 8 10
 rate per 10,000
2
4.2
6
8
rtainty in the incidence rates of VTE in the subpopulation at
range: 2–8; baseline: 4.2). (A) Scenario 1 (familial history of VTE):
4.41; (B) Scenario 2 (previous event of VTE): VTE incidence rates
tal cost-effectiveness ratio; VTE, venous thromboembolism.
Fig. 3 – Cost-effective acceptability curves derived from the
probabilistic sensitivity analysis of the incremental cost-
effectiveness ratio (euro/QALY) for scenarios 1 and 2 (3000
runs). The assumed ranges for model parameters are
speciﬁed in Table 1. CE, cost-effectiveness; QALY, quality-
adjusted life-year
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incidence of VTE increases, the no-testing option implies always
a higher QALY gain than does the combination testing strategy
(i.e., an increase in QALY loss derived from comparing the
combined strategy with the baseline strategy), and as such, the
latter is progressively less cost-effective (i.e., the ICER values
increase as negative numbers; Fig. 2). In contrast, when the fold
increase in the VTE risk during pregnancy augments, the combi-
nation testing option gains in QALY more does than the non-
testing option (i.e., reduction in QALY loss) and thus becomes
more cost-effective (i.e., the ICER values decrease as negative
numbers; Fig. 2).
Probabilistic Sensitivity Analysis
The effects of all parameter uncertainties on model outcomes
were fully evaluated by performing probabilistic sensitivity anal-
yses (Table 1). Three thousand simulations were run, and the net
costs and QALY gained were stored for each run. Figure 3
compares the cost-effectiveness acceptability curves for both
scenarios. While in scenario 1, for some realistic combinations
of model parameters, the program meets the cost-effectiveness
threshold of €40,000/QALY, in scenario 2, the negative result (i.e.,
cost-ineffective) is robust to the existing uncertainties of model
parameters. In addition, under both scenarios, a high proportion
of model runs (approximately 4% and 97% for scenario 1 and 2,
respectively) generates QALY loss (i.e., dots in the negative part of
the x-axis). This ﬁnding is the result of women being exposed to a
higher risk of VTE during (unwanted) pregnancies resulting from
OCP denial and the use of less effective contraceptive methods.
Realistic estimates of VTE incidence in the population are
problematic, due to the lack of active surveillance on VTE-related
conditions in primary care. Probabilistic sensitivity analysis was
also performed, setting the incidence rate of VTE at predeﬁned
values (baseline, lower, and upper limits of the speciﬁed range)
and deriving the proportions of cost-effective simulations when
all other model parameters were left to vary within their speciﬁed
ranges of uncertainty (Fig. 4). The proportion of ICERs below the
threshold of 40,000 increases for higher levels of VTE incidence
rates, shifting from 9% to almost 58% of all simulations. Never-
theless, the combined strategy of prescribing both genetic and
biochemical tests does not produce enough gain in QALYs to fully
offset its alternative of only prescribing biochemical tests.
The sensitivity of the incremental cost per QALY gained to
realistic changes in model parameters is shown in Figure 5 for
scenario 1 through a Tornado diagram. The diagram displays the
calculated Spearman’s rank correlation coefﬁcients as derived in the
probabilistic sensitivity analyses (@Risk5 Palisade Software). As
expected, the risk of VTE during pregnancy, the cost of the genetic
test, and the inefﬁcacy of condom use all are positively correlated
with the ICER values, meaning that increases in the former values
produce increases in the cost-effectiveness ratio and render the
combined strategy even less appealing from an economic viewpoint.
Alternative Option for Scenario 2 (Previous Event of VTE)
As shown previously in scenario 2 (previous event of VTE), the
strategy most frequently used by the sample of Italian gynecol-
ogists included in this study is cost-ineffective and leads to an
overall QALY loss. In 2009, national guidelines on this topic [31]
have suggested that the best strategy is not to test but, concom-
itantly, to prescribe second-generation oral contraceptives that
are associated with a 35% decrease in the risk of VTE (odds ratio
2.92; range 2.29–3.93 vs. baseline odds ratio 4.47 [47]). Therefore,
we modeled this option to understand how the current clinical
practice of combination testing compares with this recom-
mended alternative. As shown in Figure 6, in this case, testingwith genetic and biochemical tests is not dominated by the no-
test, low-risk OCP option. However, the ICER value remains above
the €40,000/QALY threshold of cost-effectiveness. When conduct-
ing sensitivity analysis using realistic ranges both of the inci-
dence of VTE and of the reduction in VTE risk due to the type of
OCP prescribed, it appears that the combined strategy might be
deemed cost-effective only in the presence of additional factors
that may increase the probability of VTE-related events, such as
the direct increase in the baseline VTE incidence or the use of
OCP associated with a high VTE risk.Discussion
Our study demonstrates that testing women at risk of VTE with a
battery of genetic and biochemical tests for thrombophilia before
prescribing an oral contraceptive (the most common current
practice among Italian gynecologists) is not cost-effective. This
result is consistent and robust for both subpopulations at risk
considered here (i.e., familial history of VTE and previous event of
VTE) although in the former case, there are certain factors, such
as the reduction in the cost of the genetic test or increases in VTE
incidence rates, that might render the strategy cost-effective.
Indeed, a decrease of 50% in the costs of the genetic tests would
have a signiﬁcant impact on the ICER value in the familial history
scenario, with values approaching what is generally considered
to be the cost-effectiveness threshold (approximately €40,000).
Although the trend toward a progressive automatization of large-
scale testing would probably lead to some reduction in the costs
of these tests, however, we believe that such sophisticated
diagnostic systems are unlikely to be routinely available in
hospital laboratories where most of these tests are performed,
and thus, such a dramatic reduction in costs appears rather
unrealistic in the medium term. In addition, a situation in which
the incidence of VTE was ﬁve to six times higher than our
baseline value might enable the combination testing strategy to
become cost-effective. This type of situation cannot be excluded
for two reasons. Current estimates might underestimate the real
incidence of VTE. For instance, many cases of VTE might be
diagnosed and treated in primary care and not be captured in the
hospital setting where most epidemiological studies are con-
ducted (G. Palareti, personal communication, July 20, 2010). Better
estimates of VTE incidence would be beneﬁcial to measure the
Fig. 5 – Tornado diagram showing the Spearman rank
correlation coefﬁcient calculated between the incremental
cost-effectiveness ratio (scenario 1) and the samples for each
of the input distributions. The higher the correlation
between the input and the output, the more signiﬁcant the
input is in determining the output’s value. DVT, deep-vein
thrombosis; FV, Factor V; QALY, quality-adjusted life-year;
OCP, oral contraceptive pill; OR, odds ratio; PE, pulmonary
embolism; VTE, venous thromboembolis.
Fig. 6 – Alternative Scenario 2 (previous event of VTE): Two-way
sensitivity analysis calculated for different values of the
incidence of VTE (range: 2.52–12 per 10,000; baseline 2.52)
and of the percentage reduction in the probability of VTE due
to the prescription of a low-risk OCP. ICER, incremental cost-
effectiveness ratio; OCP, oral contraceptive pill; VTE, venous
thromboembolis.
Fig. 4 – Scenario 1 (familial history of VTE): Probabilistic
sensitivity analysis conducted by setting the VTE incidence
rate at ﬁxed values (lower limit, baseline, and upper limit,
according to the values indicated in Table 1). QALY, quality-
adjusted life-year; VTE, venous thromboembolism.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 9 0 9 – 9 2 1918actual burden of the disease that is preventable by the use of
these tests.
In addition, current research in this ﬁeld is providing further
understanding of the etiology of VTE and of those additional factors,
such as the metabolic syndrome [66], that might contribute to the
risk of incurring a VTE event. Therefore, if anything, testing could be
limited to smaller subpopulations of women after having better
proﬁled their speciﬁc VTE risk and set a well-deﬁned threshold to
guide test prescription. Conversely, current practice in testing women
with familial history of VTE who ask for OCP could be improved if
gynecologists prescribed more traditional biochemical tests that are
not only substantially cheaper than their genetic counterparts but
can also diagnose genetic factors predisposing to VTE that althoughquite rare in the general population are indeed associated with an
extremely high probability of experiencing the condition.
In the case of women who have had a previous event of VTE,
we found that for all realistic parameter values, the practice of
using genetic and biochemical tests is always dominated by the
no-testing and no oral contraceptive option, thereby leading to
QALY loss. Nevertheless, it is also relevant to note that the “no-
test and no oral contraceptive” option—although supported by
economic rationality—might lead to undesired effects in patients
and clinicians. In the ﬁeld of clinical decision making and
particularly in that related to diagnostic practices and technolo-
gies, several researchers increasingly recognize the need to also
take into consideration the preferences of the clinicians or, in
other words, to also include in the assessment the negative
consequences generated by feelings of disappointment and
regret occurring when a clinician appears to not do all that is
available to diagnose or cure the patient effectively [67,68]. This
aspect might be even more important, as in the present situation,
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 9 0 9 – 9 2 1 919when the clinician’s decision affects such a relevant aspect of a
women’s life, that is, family planning, with the concrete risk that
not prescribing genetic testing or an oral contraceptive might
greatly harm the clinician-patient trust relationship.
This ﬁnding is also why current national guidelines recom-
mend an alternative prescription strategy that would result from
the anamnesis of the patient, rather than from the results of
genetic tests and, in case of personal history of VTE, consists in
choosing a low-risk type of oral contraceptive (second genera-
tion). When comparing the combined strategy (followed by a
good proportion of our sample of gynecologists) with this hypo-
thetical (though recommended) baseline alternative, we found
the former to remain cost-ineffective. Thus, following the current
national guideline would not only represent an improvement
over the most common practice of Italian gynecologists but also
offer a better alternative to maintain a good patient-clinician
relationship. As such, a better dissemination of the national
guidelines and their continuous discussion within the medical
community is likely to help internalize these recommendations
and dissipate fear among clinicians of losing patients or being
held accountable for not testing them.
As to the policy implications of this study, despite the limited
economic burden for the Italian NHS that genetic testing for FVL
and FII represents, the primary consideration is the opportunity
cost, that is, the beneﬁts forgone for having misallocated scarce
resources. Given that the current practices are cost-ineffective
and may even lead to QALY loss, there is an urgent need for
policymakers to put concrete actions in place to monitor and
eventually steer clinicians’ prescribing behavior for these genetic
tests. Ideally, policymakers could limit reimbursement only to
those test applications that are believed to be appropriate and
cost-effective. Policymakers might not want to institute these
unpopular measures. This decision should not prevent them
from promoting better data-gathering systems both on the
burden of VTE and on its risk factors that might lead to a better
risk proﬁling and more targeted use of these tests. The assess-
ment of new technologies—especially devices and diagnostics—
should follow an iterative process and allow new evidence on
potential beneﬁts to emerge [13]; therefore, this type of policy
action appears equally important. For instance, the value of
additional information to better inform these decisions could be
calculated [69], so that policymakers were not forced to guide
clinical practice on genetic testing in the presence of major
uncertainties regarding critical epidemiological parameters
related to VTE, but rather invested public resources to gather
better evidence on these aspects and take a more informed
decision. Epidemiological modeling and cost-effectiveness anal-
ysis are meant to also serve this aim, which is to evaluate and
eventually highlight the existence of critical parameters for
which additional information would be required for effective
and cost-effective policy measures to be implemented.Limitations and Conclusions
Although the above analysis has been conducted aiming at a
rigorous framework, with soundmodel structuring and parameter-
ization [70], it is clearly not spared from limitations. First, we have
based our model data on the context of interest as much as
possible, but still many input data (especially of epidemiological
nature) were taken from the literature and from different settings.
Second, our models were generated on the basis of decision
analysis exercise conducted by a limited number of respondents
(250 gynecologists) and might not faithfully represent the clinical
practice in the entire country. In particular, we cannot exclude that
only those clinicians who were better informed about genetic
testing or had received speciﬁc education regarding this topic weremore prone to complete the questionnaire. As such, we may have
selected gynecologists with a more appropriate prescribing behav-
ior or who are more self-conscious regarding their answers.
Despite giving only a partial picture of the phenomenon, we still
deem this approach more rigorous for the purpose of this study
than modeling hypothetical clinical behaviors or developing deci-
sion trees exclusively on the basis of expert opinion. Third, the
administrative data used to reconstruct the most common treat-
ment procedures for VTE in the Italian context might suffer from
incompleteness due to underreporting. What has emerged from
our analysis, however, appears consistent with international
clinical guidelines for the treatment of VTE. Therefore, adminis-
trative data represent a very rich and detailed source of informa-
tion and a reliable alternative to gathering microdata directly
through medical records. Fourth, our cost estimates are neither
comprehensive because we have neglected in our calculations
non-NHS medical costs, such as those associated with contra-
ceptive methods, nor fully generalizable given that most of these
costs are based on the accounting system of a single hospital. Fifth,
we have adopted the UK indicative threshold of €40,000 to €50,000/
QALY for cost-effectiveness analyses. In Italy, at present, there is
no indication by policymakers of such a criterion for decision
making and this same value might not be deemed appropriate in
the future. To better contribute to inform, and potentially change,
the current genetic testing practice, we believe that it was still
important to compare our results with a value that, although with
great limitations [71], is an internationally established reference.
The present study provides a number of concrete suggestions to
improve both clinical decision making and policy choices. Not only
does this work indicate the way to a better and more cost-effective
clinical practice, but it also pinpoints those strategies that by being
more feasible and acceptable from the clinicians’ and policy-
makers’ point of view have a greater chance of being followed.Acknowledgments
The authors thank all the members of the PRIN project
(W. Ricciardi, S. Boccia, P. Villari, C. De Vito, E. Di Maria, F. Dagna
Bricarelli, D. Coviello, and C. Izzotti) for their collaboration and
support during the course of the study; M. Costa, G. Palareti, and
I. Martinelli for advice on epidemiological and medical issues
related to VTE; A. Susi for support with preliminary data analysis;
M. Esposto, director of the budgeting and accounting ofﬁce, and
G. Lo Pinto, director of the thrombosis center, of the Galliera
Hospital for cost data; the Friuli Venezia Giulia region for hospital
discharge records; and the Italian Society of Gynecologists and
Obstetricians (SIGO) for support with the administration of the
decision analysis questionnaire.
Source of ﬁnancial support: The project was funded by a grant
of the Italian Ministry of Higher Education and Research within
the PRIN program 2007.Supplemental Materials
Supplemental material accompanying this article can be found in
the online version as a hyperlink at http://dx.doi.org/10.1016/j.
jval.2013.05.003 or, if a hard copy of article, at www.valueinhealth
journal.com/issues (select volume, issue, and article).
R E F E R E N C E S[1] House of Lords Science and Technology Committee. Genomic Medicine.
London: The Stationery Ofﬁce, 2009.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 9 0 9 – 9 2 1920[2] Burton H. Genetics and Mainstream Medicine. Cambridge: PHG
Foundation, 2011.
[3] Col NF. The use of gene test to detect hereditary predisposition to
chronic disease: is cost-effectiveness analysis relevant? Med Decis
Making 2003;23:441–8.
[4] Zika E, Gurwitz D, Ibarreta D. Pharmacogenetics and
Pharmacogenomics: State-of-the-Art and Potential Socio-Economic
Impacts in the EU. Luxembourg: Ofﬁce of the Ofﬁcial Publications of the
EU Communities, 2006.
[5] Mansﬁeld E, O’Leary TJ, Gutman SI. Food and drug administration of
in vitro diagnostic devices. J Mol Diagn 2005;7:2–7.
[6] Ramsey SD, Veenstra DL, Garrison LP Jr., et al. Toward evidence-based
assessment for coverage and reimbursement of laboratory-based
diagnostic and genetic tests. Am J Manag Care 2006;12:197–202.
[7] Hogarth S, Javitt G, Melzer D. The current landscape for direct-to-
consumer genetic testing: legal, ethical, and policy issues. Annu Rev
Genomics Hum Genet 2008;9:161–82.
[8] Haddow JE, Palomaki GE. ACCE: a model process for evaluating data on
emerging genetic tests. In: Khoury MJ, Little J, Burke W, eds., Human
Genome Epidemiology: A Scientiﬁc Foundation for Using Genetic
Information to Improve Health and Prevent Disease. New York: Oxford,
2004:217–33.
[9] Teutsch SM, Bradley LA, Palomaki GE, et al. The Evaluation of Genomic
Applications in Practice and Prevention (EGAPP) initiative: methods of
the EGAPP Working Group. Genet Med 2009;11:3–14.
[10] Carlson JJ, Henrikson NB, Veenstra DL, et al. Economic analyses of
human genetics services: a systematic review. Genet Med 2005;7:519–23.
[11] Rogowski W. Genetic screening by DNA technology: a systematic
review of health economic evidence. Int J Technol Assess Health Care
2006;22:327–37.
[12] Grosse SD, Wordsworth S, Payne K. Economic methods for valuing the
outcomes of genetic testing: beyond cost-effectiveness analysis. Genet
Med 2008;10:648–54.
[13] Drummond M, Grifﬁn A, Tarricone R. Economic evaluation for devices
and drugs—same or different? Value Health 2009;12:402–4.
[14] Frønsdal KB, Facey K, Klemp M, et al. Health technology assessment to
optimize health technology utilization: using implementation
initiatives and monitoring processes. Int J Technol Assess Health Care
2010;26:309–16.
[15] Berger ML, Mamdani M, Atkins D, Johnson ML. Good research practices
for comparative effectiveness research: deﬁning, reporting and
interpreting nonrandomized studies of treatment effects using
secondary data sources: the ISPOR Good Research Practices for
Retrospective Database Analysis Task Force Report—part I. Value
Health 2009;12:1044–52.
[16] Cox E, Martin BC, Van Staa T, et al. Good research practices for
comparative effectiveness research: approaches to mitigate bias and
confounding in the design of non-randomized studies of treatment
effects using secondary data sources: the ISPOR Good Research
Practices for Retrospective Database Analysis Task Force–part II. Value
Health 2009;12:1053–61.
[17] Berger ML, Dreyer N, Anderson F, et al. Prospective observational
studies to assess comparative effectiveness: the ISPOR Good Research
Practices Task Force Report. Value Health 2012;15:217–30.
[18] Johnson ML, Crown W, Martin BC, et al. Good research practices for
comparative effectiveness research: analytic methods to improve
causal inference from nonrandomized studies of treatment effects
using secondary data sources: the ISPOR Good Research Practices for
Retrospective Database Analysis Task Force Report—part III. Value
Health 2009;12:1062–73.
[19] White RH. The epidemiology of venous thromboembolism. Circulation
2003;107(23, Suppl. 1):I4–8.
[20] Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. A population-based
perspective of the hospital incidence and case-fatality rates of deep
vein thrombosis and pulmonary embolism. The Worcester DVT Study.
Arch Intern Med 1991;151:933–8.
[21] Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep
vein thrombosis and pulmonary embolism: a 25-year population-based
study. Arch Intern Med 1998;158:585–93.
[22] Nordstrom M, Lindblad B, Bergqvist D. A prospective study of the
incidence of deep-vein thrombosis within a deﬁned urban population.
J Intern Med 1992;232:155–60.
[23] Spencer FA, Emery C, Lessard D, et al. The Worcester Venous
Thromboembolism study: a population-based study of the clinical
epidemiology of venous thromboembolism. J Gen Intern Med
2006;21:722–7.
[24] Oger E. Incidence of venous thromboembolism: a community-based
study in Western France. EPIGETBO Study Group. Groupe d’Etude de la
Thrombose de Bretagne Occidentale. Thromb Haemost 2000;83:657–60.
[25] Cohen AT, Edmondson RA, Phillips MJ, et al. The changing pattern of
venous thromboembolic disease. Haemostasis 1996;26:65–71.[26] Lindblad B, Sternby NH, Bergqvist D. Incidence of venous
thromboembolism veriﬁed by necropsy over 30 years. BMJ
1991;302:709–11.
[27] Sandler DA, Martin JF. Autopsy proven pulmonary embolism in
hospital patients: are we detecting enough deep vein thrombosis? J R
Soc Med 1989;82:203–5.
[28] Gohil R, Peck G, Sharma P. The genetics of venous thromboembolism: a
meta-analysis involving approximately 120,000 cases and 180,000
controls. Thromb Haemost 2009;102:360–70.
[29] Dallapiccola B, Torrente I, Morena A, Mingarelli R. Censimento delle
strutture di Genetica Medica e dei test genetici in Italia-Anno 2004.
Analysis 2006;6/7:263–78.
[30] Dallapiccola B, Agolini E, Morena A, et al. Censimento 2007 delle attività
delle strutture di Genetica Medica in Italia. Analysis 2009;4/5:207–32.
[31] Consensus Conference Roma, 18–19 September 2008. Prevenzione delle
complicanze trombotiche associate all’uso di estro progestinici in età
riproduttiva. Available from: http://www.snlg-iss.it/cms/ﬁles/
CC_EP_tromboﬁlia.pdf. [Accessed May 30, 2012].
[32] Grody WW, Grifﬁn JH, Taylor AK, et al. American College of Medical
Genetics consensus statement on factor V Leiden mutation testing.
Genet Med 2001;3:139–48.
[33] European Genetics Foundation, Cardiovascular Disease Educational
and Research Trust, International Union of Angiology, et al.
Thrombophilia and venous thromboembolism: international
consensus statement. Guidelines according to scientiﬁc evidence. Int
Angiol 2005;24:1–26.
[34] Clark P, Twaddle S, Walker ID, et al. Cost-effectiveness of screening for
the factor V Leiden mutation in pregnant women. Lancet
2002;359:1919–20.
[35] Smith KJ, Monsef BS, Ragni MV. Should female relatives of factor V
Leiden carriers be screened prior to oral contraceptive use? A cost-
effectiveness analysis. Thromb Haemost 2008;100:447–52.
[36] Wu O, Robertson L, Twaddle S, et al. Screening for thrombophilia in
high-risk situations: a meta-analysis and cost-effectiveness analysis.
Br J Haematol 2005;131:80–90.
[37] Lidegaard Ø, Edström B, Kreiner S. Oral contraceptives and venous
thromboembolism: a ﬁve-year national case-control study.
Contraception 2002;65:187–96.
[38] Hansson PO, Sörbo J, Eriksson H. Recurrent venous thromboembolism
after deep vein thrombosis. Arch Intern Med 2000;160:769–74.
[39] Smith KJ, Brenna S, Monsef, et al. Should female relatives of factor
V Leiden carriers be screened prior to oral contraceptive use?
A cost-effectiveness analysis. Thromb Haemost 2008;100:447–52.
[40] Marchetti M, Quaglini S, Barosi G. Cost-effectiveness of screening and
extended anticoagulation for carriers of both factor V Leiden and
prothrombin G20210A. QJM 2001;94:365–72.
[41] Sørensen HT, Horvath-Puho E, Pedersen L, et al. Venous
thromboembolism and subsequent hospitalisation due to acute arterial
cardiovascular events: a 20-year cohort study. Lancet 2007;370:1773–9.
[42] Rosendaal FR. Risk factors for venous thrombotic disease. Thromb
Haemost 1999;82:610–9.
[43] Department of Reproductive Health, World Health Organization.
Medical Eligibility Criteria for Contraceptive Use (4th ed.). Geneva:
World Health Organization, 2010. Available from: http://www.who.int/
reproductivehealth/publications/family_planning/9789241563888/en/
index.html [Accessed May 30, 2012].
[44] Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal
contraception and risk of venous thromboembolism: national follow-
up study. BMJ 2009;339:b2890.
[45] Carrier M, Le Gal G, Wells PS, Rodger MA. Systematic review: case-
fatality rates of recurrent venous thromboembolism and major
bleeding events among patients treated for venous thromboembolism.
Ann Intern Med 2010;152:578–89.
[46] Wu O, Robertson L, Twaddle S, et al. Screening for thrombophilia in
high-risk situations: systematic review and cost-effectiveness analysis.
The Thrombosis: Risk and Economic Assessment of Thrombophilia
Screening (TREATS) study. Health Technol Assess 2006;10:1–110.
[47] Manzoli L, De Vito C, Marzuillo C, et al. Oral contraceptives and venous
thromboembolism: a systematic review and meta-analysis. Drug Saf
2012;35:191–205.
[48] Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of
acute deep venous thrombosis. Ann Intern Med 1996;125:1–7.
[49] Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic
thromboembolic pulmonary hypertension after pulmonary embolism.
N Engl J Med 2004;350:2257–64.
[50] Laczkovics C, Grafenhofer H, Kaider A, et al. Risk of recurrence after a
ﬁrst venous thromboembolic event in young women. Haematologica
2007;92:1201–7.
[51] Duriseti RS, Brandeau ML. Cost-effectiveness of strategies for
diagnosing pulmonary embolism among emergency department
patients presenting with undifferentiated symptoms. Ann Emerg Med
2010;56:321–32.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 9 0 9 – 9 2 1 921[52] O’Meara JJ, McNutt RA, Evans AT, et al. A decision analysis of
streptokinase plus heparin as compared to heparin alone for deep vein
thrombosis. N Engl J Med 1994;330:1864–9.
[53] Cadilhac DA, Dewey HM, Vos T, et al. The health loss from ischemic
stroke and intracerebral hemorrhage: evidence from the North East
Melbourne Stroke Incidence Study (NEMESIS). Health Qual Life
Outcomes 2010;8:49.
[54] Clarke P, Gray A, Holman R. Estimating utility values for health states
of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis
Making 2002;22:340–9.
[55] McKenna SP, Ratcliffe J, Meads DM, Brazier JE. Development and
validation of a preference-based measure derived from the Cambridge
Pulmonary Hypertension Outcome Review (CAMPHOR) for use in cost
utility analyses. Health Qual Life Outcomes 2008;6:65.
[56] Amaral G, Foster DG, Biggs MA, et al. Public savings from the
prevention of unintended pregnancy: a cost analysis of family planning
services in California. Health Serv Res 2007;42:1960–80.
[57] Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia: part 1.
Thromb Haemost 1996;76:651–62.
[58] Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia: part 2.
Thromb Haemost 1996;76:824–34.
[59] ISTAT. Cause di morte Anno 2002. Annuario n. 18 – 2007. Available
from: http://www3.istat.it/dati/catalogo/20070405_00/ann_07_18_cause
_di_morte_2002.pdf. [Accessed May 30, 2012].
[60] Kind P, Dolan P, Gudex C, Williams A. Variations in population health
status: results from a United Kingdom national questionnaire survey.
BMJ 1998;316:736–41.
[61] Kessler CM. The link between cancer and venous thromboembolism: a
review. Am J Clin Oncol 2009;32(4, Suppl.):S3–7.[62] AIFA. Prontuario Farmaceutico Nazionale. Rome: AIFA, 2005.
[63] National Institute for Clinical Excellence. Guide to the Methods of
Technology Appraisal. London: National Institute for Clinical
Excellence, 2004.
[64] Briggs AH. Holding uncertainty in economic evaluation and presenting
the results. In: Drummond MF, McGuire A, eds., Economic Evaluation in
Health Care: Merging Theory with Practice. Oxford: Oxford University
Press, 2001;172–214.
[65] Appleby J, Devlin N, Parkin D. NICE’s cost effectiveness threshold. BMJ
2007;335:358–9.
[66] Jang MJ, Choi W, Bang S-M, et al. Metabolic syndrome is associated with
venous thromboembolism in the Korean population. Arterioscler
Thromb Vasc Biol 2009;29:311–5.
[67] Smith RD. Is regret theory an alternative basis for estimating the value
of healthcare interventions? Health Policy 2000;37:105–15.
[68] Hozo I, Djulbegovic B. When is diagnostic testing inappropriate or
irrational? Acceptable regret approach. Med Decis Making
2008;28:540–53.
[69] Briggs A, Schulpher M, Claxton K. Decision Modelling for Health
Economic Evaluation. Oxford: Oxford University Press, 2006.
[70] Philips Z, Bojke L, Sculpher M, et al. Good practice guidelines for
decision-analytic modelling in health technology assessment: a review
and consolidation of quality assessment. Pharmacoeconomics
2006;24:355–71.
[71] Grosse SD. Assessing cost-effectiveness in healthcare: history of the
$50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res
2008;8:165–78.
